Victrex (VCT) Q3 2025 TU earnings summary

Executive summary

• CEO transition: Jakob Sigurdsson to retire, James Ralph appointed as successor, bringing sector experience and a growth track record.

• Q3 sales volume up 8% year-over-year, led by Sustainable Solutions, while Medical revenues, especially Spine, remained soft.

• Revenue declined 3% year-over-year in Q3 due to adverse mix and lower ASP, despite volume growth.

• Business remains differentiated with innovation focus and well-invested assets in the UK, medical, and China, positioning for improved profitability.

• Cost discipline remains strong, with capex and inventory reduction on track.

Financial highlights

• Q3 sales volume: 1,057 tons (+8% year-over-year); nine months: 3,075 tons (+13% year-over-year).

• Q3 revenue: £71.5m (down 3% year-over-year); nine months: £217.3m (up 2% year-over-year).

• Q3 ASP: £68/kg (down 11% year-over-year); nine-month ASP: £71/kg (down 10% year-over-year).

• Net debt at 30 June 2025: £42.8m (Q3 2024: £39.6m), including £19.7m cash.

• Currency headwind for FY25 at £9m adverse impact at PBT level.

Outlook and guidance

• Full-year volume growth expected at least high single digits, in line with guidance.

• H2 underlying PBT targeted to be slightly improved on H1, but similar result likely if Q3 trends persist.

• Q4 faces tougher comparison; ongoing macroeconomic uncertainty and £9m currency headwind for FY25.

• Currency for FY26 tracking at £3-4m adverse to FY25; hedging covers over 50% of US dollar and Euro exposure for FY26.

• Macroeconomic uncertainty and adverse sales mix remain key considerations for the remainder of FY25.